GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » Financial Strength

Bluejay Diagnostics (Bluejay Diagnostics) Financial Strength : 7 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics Financial Strength?

Bluejay Diagnostics has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Bluejay Diagnostics's interest coverage with the available data. As of today, Bluejay Diagnostics's Altman Z-Score is 0.00.


Competitive Comparison of Bluejay Diagnostics's Financial Strength

For the Medical Devices subindustry, Bluejay Diagnostics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bluejay Diagnostics's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's Financial Strength distribution charts can be found below:

* The bar in red indicates where Bluejay Diagnostics's Financial Strength falls into.



Bluejay Diagnostics Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Bluejay Diagnostics's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-2.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.19 Mil.

Bluejay Diagnostics's Interest Coverage for the quarter that ended in Dec. 2023 is

GuruFocus does not calculate Bluejay Diagnostics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Bluejay Diagnostics Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Bluejay Diagnostics's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.163 + 0.19) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Bluejay Diagnostics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bluejay Diagnostics  (NAS:BJDX) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Bluejay Diagnostics has the Financial Strength Rank of 7.


Bluejay Diagnostics Financial Strength Related Terms

Thank you for viewing the detailed overview of Bluejay Diagnostics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Bluejay Diagnostics (Bluejay Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720
Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing, manufacturing, and marketing of clinical diagnostic products that improve the quality of medical diagnoses. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. The company is a provider of rapid tests for infectious, inflammatory, and metabolic diseases by the Symphony platform.
Executives
Svetlana Dey director, 10 percent owner 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey director, 10 percent owner, officer: Chief Technology Officer 360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally officer: CFO 66 MELANIE LANE, SYOSSET NY 11791
Jason Cook officer: Chief Technology Officer 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher officer: Chief Financial Officer 67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth director, 10 percent owner 4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder officer: Chief Financial Officer 360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani director C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman director 109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase director 39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089